Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.63 |
| ▸ | CA1 | P00915 | 4/20 | 0.63 |
| ▸ | CA12 | O43570 | 2/20 | 0.63 |
| ▸ | CA9 | Q16790 | 2/20 | 0.63 |
| ▸ | MMP1 | P03956 | 1/20 | 0.63 |
| ▸ | MMP2 | P08253 | 1/20 | 0.63 |
| ▸ | MMP9 | P14780 | 1/20 | 0.63 |
| ▸ | MMP8 | P22894 | 1/20 | 0.63 |
| ▸ | MMP13 | P45452 | 1/20 | 0.63 |
| ▸ | CA3 | P07451 | 1/20 | 0.63 |
| ▸ | CA4 | P22748 | 1/20 | 0.63 |
| ▸ | CA6 | P23280 | 1/20 | 0.63 |
| ▸ | CA5A | P35218 | 1/20 | 0.63 |
| ▸ | CA7 | P43166 | 1/20 | 0.63 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.63 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.63 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.63 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21416015 | 0.87 | MEN1 (0.66) | CA2CA1CA12CA9MMP1 | |
| SCHEMBL28649866 | 0.85 | CYP19A1 (0.56) | CA2CA1CA12CA9MMP1 | |
| SCHEMBL6302342 | 0.85 | CYP19A1 (0.59) | CA2CA1CA12CA9MMP1 | |
| SCHEMBL667271 | 0.85 | CA1 (0.65) | CA2CA1CA12CA9MMP1 | |
| Diethylamine SCHEMBL4006972 | 0.84 | CA1 (0.59) | CA2CA1CA12CA9MMP1 | |
| SCHEMBL11441255 | 0.82 | MEN1 (0.60) | CA2CA1CA12CA9MMP1 | |
| SCHEMBL17115759 | 0.82 | CA1 (0.64) | CA2CA1CA12CA9MMP1 | |
| SCHEMBL28928577 | 0.82 | CA2 (0.61) | CA2CA1CA12CA9MMP1 | |
| SCHEMBL6304571 | 0.82 | MEN1 (0.60) | CA2CA1CA12CA9MMP1 | |
| SCHEMBL3685056 | 0.82 | MEN1 (0.62) | CA2CA1CA12CA9MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6395899-B2 | PREPARING CYCLIC 2,2-BIS(DIFLUORAMINO)-N,N'-DINITRO-1,3-PROPANEDIAMINE VIA REACTING WITH FORMALDEHYDE OR GLYOXAL; PRODUCING 5,5-BIS(DIFLUORAMINO)HEXAHYDRO-1,3-DINITROPYRIMIDINE (RNFX); FOR EXPLOSIVES, PROPELLANTS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY | 2002-05-28 | — | — | US | disclosed |
| US-20020007063-A1 | Preparing cyclic 2,2-bis(difluoramino)-N,N'-dinitro-1,3-propanediamine via reacting with formaldehyde or glyoxal; producing 5,5-bis(difluoramino)hexahydro-1,3-dinitropyrimidine (RNFX); for explosives, propellants | CHAPMAN ROBERT DALE (US) | 2002-01-17 | — | — | US | disclosed |
| US-6310204-B1 | 5,5-bis(difluoramino)hexahydro-1,3-dinitropyrimidine (RNFX) and certain electronegatively substituted pyrimidines | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY | 2001-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020007063-A1 | Preparing cyclic 2,2-bis(difluoramino)-N,N'-dinitro-1,3-propanediamine via reacting with formaldehyde or glyoxal; producing 5,5-bis(difluoramino)hexahydro-1,3-dinitropyrimidine (RNFX); for explosives, propellants | RNF5, RNF168, RBX1 | CA2 4441/4885CA1 3698/4885CA12 4686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.